Zolimomab Biosimilar – Anti-CD5 mAb – Research Grade from ProteoGenix; catalogue PX-TA1226; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Zolimomab Biosimilar – Anti-CD5 mAb – Research Grade: A Promising Antibody for Therapeutic Targeting
Zolimomab Biosimilar, also known as Anti-CD5 monoclonal antibody (mAb), is a novel therapeutic agent that has gained significant attention in the field of immunotherapy. This biosimilar version of Zolimomab is a highly specific antibody that targets the CD5 antigen, a cell surface protein found on T cells and B cells. In this article, we will explore the structure, activity, and potential applications of Zolimomab Biosimilar as a promising antibody for therapeutic targeting.
Zolimomab Biosimilar is a recombinant humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the CD5 antigen, while the constant region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Zolimomab Biosimilar exerts its activity by binding to the CD5 antigen, which is overexpressed on the surface of T cells and B cells in various hematological malignancies. This binding leads to the activation of signaling pathways that induce cell death and inhibit cell proliferation. Moreover, Zolimomab Biosimilar can also recruit immune effector cells, such as natural killer (NK) cells, to induce ADCC and CDC against CD5-positive cells.
Zolimomab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various hematological malignancies, including T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma. In addition, it has also shown potential in the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, where CD5-positive T cells play a crucial role in disease pathogenesis.
Compared to the original Zolimomab, the biosimilar version offers several advantages. First, it is more cost-effective, making it more accessible to patients. Second, it has a lower potential for immunogenicity, as it is produced using advanced recombinant DNA technology. Third, it has a longer half-life, which allows for less frequent dosing and improved patient compliance.
In conclusion, Zolimomab Biosimilar is a promising antibody for therapeutic targeting due to its highly specific binding to the CD5 antigen and its potential to induce cell death and immune-mediated cytotoxicity. Its structure, activity, and potential applications make it a valuable addition to the arsenal of immunotherapeutic agents. With ongoing research and development, Zolimomab Biosimilar holds great promise for the treatment of various hematological malignancies and autoimmune diseases.
ProteoGenix catalogue number PX-TA1226. For research use only.
Target: Zolimomab Biosimilar – Anti-CD5 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Zolimomab Biosimilar – Anti-CD5 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
